About the Emerging Infectious Diseases journal
Emerging Infectious Diseases is an open access journal published monthly by the Centers for Disease Control and Prevention (CDC). The journal is published online and also has a limited print run on acid free paper that meets the requirements of ANSI/NISO Z39.48-1984 (Permanence of Paper). Publication in EID enables compliance with the NIH Public Access Policy.
Emerging Infectious Diseases follows the International Committee of Medical Journal Editors recommendations for the conduct, reporting, editing, and publishing of scholarly work in medical journals. The journal’s peer review process allows for critical assessment of submitted manuscripts by experts who are usually not part of its editorial staff. As an independent publication, the journal’s peer-review process operates independently from CDC’s clearance processes.
The conclusions, findings, and opinions expressed by authors contributing to Emerging Infectious Diseases do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by the Public Health Service or by the U.S. Department of Health and Human Services.
Contact us for additional information.
Open Access and Usage
Emerging Infectious Diseases is an open access journal in the public domain. All content is freely available without charge to the user or his/her institution. In accordance with the Budapest Open Access Initiative definition of Open Access, users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. Because the journal is in the public domain, its usage policy also conforms to conditions set for by Creative Commons.
Emerging Infectious Diseases does request a proper citation be included for its content and that any user indicate clearly if changes have been made.
Emerging Infectious Diseases grants authors permission to self-archive their articles without fees or permission and grants institutions permission to preserve a second copy of articles published by their researchers in the institutional repository.
The peer review process for Emerging Infectious Diseases is managed via an online editorial system (Manuscript Central). EID operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but reviewer reports provided to authors are anonymous.
The Editor-in-Chief screens submissions, rejects unsuitable manuscripts, and assigns articles deemed appropriate for peer review to associate editors or members of the editorial board. Manuscripts accepted for peer review will generally be reviewed by experts who are provided with a copy of the manuscript, author checklist, and associated files, such as graphics or technical appendices. Those reviewers evaluate whether the manuscript is scientifically sound and has public health utility. The associate editors or members of the editorial board evaluate peer reviewers’ recommendations and send their decision to the Editor-in-Chief, who has the final decision on accepting or rejecting manuscripts.
Emerging Infectious Diseases follows the ICMJE recommendations for Protection of Research Participants.
In brief, when studies involve human participants, authors are responsible for including a statement that those studies have been approved by the appropriate institutional or national research ethics committee and have been performed in accordance with the ethical standards noted in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
In brief, when reporting experiments on animals, authors should indicate whether institutional and national standards for the care and use of laboratory animals were followed.
Emerging Infectious Diseases reserves the right to request that author’s provide documentation from the review board or ethics committee confirming approval of the research.
Archiving Full-Text Content and Abstracts
Full abstracts for all articles and online reports that are published with abstracts are accessible via PubMed.gov. Each article contains a digital object identifier (DOI) link to the original, complete article on the EID website.
EMERGING INFECTIOUS DISEASES ® is a registered service mark of the US Department of Health and Human Services. Its Registration Number 4,972,553 is issued by the United States Patent & Trademark Office (USPTO).
2018 Impact Factor (Journal Citation Reports, 2017)
EID’s 2017 impact factor is 7.42, first among open-access infectious disease journals and fourth among the 88 tracked infectious disease journals. EID’s high impact factor indicates that articles published in the journal during the last 2 years have been cited an average of more than 7 times during the past year.
2018 Google Scholar h-Index
Ranked 2nd of top 20 publications in Epidemiology and 2nd among open-access journals.
- Ranked 3rd among top 20 publications in Communicable Diseases and 1st among open-access journals.
2017 Scopus CiteScore Metrics for Serials
- CiteScore = 4.78
- Ranked 15th out of 262 infectious diseases journals (94th percentile)
- Ranked 8th out of 108 microbiology journals (93rd percentile)
- Ranked 11th out of 87 epidemiology infectious diseases journals (87th percentile)
Indexing and Full Text Content
Emerging Infectious Diseases is indexed in Index Medicus/Medline, Current Contents, Excerpta Medica, Literature, Arts, and Medicine Database. Full text content is available in PubMed Central, CrossRef, and LinkOut.
Full abstracts for all of EID’s Ahead-of-Print articles and online reports are now accessible via PubMed.gov, in addition to our current and past publications. Each article contains a digital object identifier (DOI) link to the original, complete article on the EID website.
Submissions and Acceptance
- Emerging Infectious Diseases receives more than 2,100 manuscripts per year (most unsolicited, some invited) from authors around the world.
- Approximately 25% of submitted articles are accepted.
- 4,709 subscribers to print version
- 109,607 subscribers to table of contents emails (subscribe here)
- More than 7 million page visits to EID’s website annually (CDC Web Statistics)
- More than 3 million views in 2017 for EID’s articles in PubMed Central
- 171,722 unique subscribers to any of EID’s GovDelivery emails